Drug Prices Remain High and Unpredictable as Beneficiaries Look to Lawmakers for a Fix
Medicare drug prices keep rising faster than inflation, and 8 in 10 adults say the cost of prescription drugs is
The Inflation Reduction Act (IRA) takes important steps to reduce drug prices and lower costs for people with Medicare and the program, such as capping beneficiary out-of-pocket spending; requiring Medicare to negotiate drug prices; and expanding eligibility for the full Part D low-income subsidy (LIS). We support an implementation process that centers the beneficiary experience and look forward to building upon these landmark policies.
Medicare drug prices keep rising faster than inflation, and 8 in 10 adults say the cost of prescription drugs is
A recently released report from the Urban Institute shows that a firm limit on out-of-pocket (OOP) Part D costs, like
A new brief from the Kaiser Family Foundation (KFF) examines the often extreme cost liability that Part B covered drugs—typically,
A new analysis from the AARP Public Policy Institute finds drug companies have increased prices for many brand name Part
This week, Medicare Rights submitted comments on a proposed rule that would make some important changes to Medicare Advantage (MA)
This week, over 90 advocacy and other organizations sent a letter to U.S. Senators, urging them to pass the drug
Medicare Rights joined over 90 groups to urge US Senators to pass drug pricing reforms through reconciliation.
Last week, the Centers for Medicare & Medicaid Services (CMS) released a new proposed rule that would require Medicare Part
The Kaiser Family Foundation (KFF) recently released an issue brief detailing the prescription drug proposals in Build Back Better (BBB), the bill that
This Thanksgiving, we are grateful to advocates like you, for your tireless work to improve policies, programs, and lives. The
Medicare drug prices keep rising faster than inflation, and 8 in 10 adults say the cost of prescription drugs is
A recently released report from the Urban Institute shows that a firm limit on out-of-pocket (OOP) Part D costs, like
A new brief from the Kaiser Family Foundation (KFF) examines the often extreme cost liability that Part B covered drugs—typically,
A new analysis from the AARP Public Policy Institute finds drug companies have increased prices for many brand name Part
This week, Medicare Rights submitted comments on a proposed rule that would make some important changes to Medicare Advantage (MA)
This week, over 90 advocacy and other organizations sent a letter to U.S. Senators, urging them to pass the drug
Medicare Rights joined over 90 groups to urge US Senators to pass drug pricing reforms through reconciliation.
Last week, the Centers for Medicare & Medicaid Services (CMS) released a new proposed rule that would require Medicare Part
The Kaiser Family Foundation (KFF) recently released an issue brief detailing the prescription drug proposals in Build Back Better (BBB), the bill that
This Thanksgiving, we are grateful to advocates like you, for your tireless work to improve policies, programs, and lives. The